Gilead Sciences has said it will stop the development of its cancer antibody magrolimab in blood cancer myelodysplastic syndromes (MDS) after disappointing results in a ph
Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years a
Just a month after AbbVie and Genmab got FDA approval for Epkinly in one form of non-Hodgkin’s lymphoma, the partners are now preparing to file for a second.
Last year, Nkarta was celebrating data which showed that its natural killer (NK) cell therapy for acute myeloid leukaemia (AML) was showing remarkable efficacy in hard-to-
In another look back to ASCO 2023, pharmaphorum editor-in-chief Jonah Comstock spoke with Janssen's Martin Vogel and Edmond Chan, EMEA leads for oncology and haematology, respectively.
